XLO - Xilio Therapeutics GAAP EPS of -$0.83 beats by $0.06
2023-05-09 08:54:44 ET
- Xilio Therapeutics press release ( NASDAQ: XLO ): Q1 GAAP EPS of -$0.83 beats by $0.06 .
- Cash and cash equivalents were $93.3 million as of March 31, 2023, compared to $120.4 million as of December 31, 2022.
For further details see:
Xilio Therapeutics GAAP EPS of -$0.83 beats by $0.06